Zhejiang Jolly Pharmaceutical (300181.SZ) announced the 2024 restricted stock incentive plan (draft), intending to grant up to 6.605 million shares of restricted stocks to incentive recipients, involving Renminbi A-share common stocks, accounting for approximately 0.94% of the total share capital of the company as of the announcement date of the incentive plan. Among them, 5.855 million shares of restricted stocks will be granted initially, with 0.75 million shares reserved. The grant price is 8.07 yuan per share.

This incentive plan is intended to first grant a total of 112 incentive recipients. The incentive plan is valid from the date of the initial grant of restricted stocks to the incentive recipients, until the date when all the restricted stocks granted to the incentive recipients become vested or are invalidated, lasting for a maximum of 60 months.